Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant’s blockbuster shots.

Novo Nordisk's (NVO) stock price dropped following Eli Lilly's announcement of positive Phase 3 trial results for its oral weight loss drug orforglipron—that helped patients shed weight and control blood sugar,

Eli Lilly and Novo Nordisk dominate the billion-dollar weight loss drug market. Lilly has announced positive trial results from a candidate that could be a game changer in this area of high demand. Patients self-administer,